- Academic Editor
Background: Alzheimer’s disease (AD) is a condition that affects the nervous system and that requires considerably more in-depth study. Abnormal Nicotinamide Adenine Dinucleotide (NAD+) metabolism and disulfide levels have been demonstrated in AD. This study investigated novel hub genes for disulfide levels and NAD+ metabolism in relation to the diagnosis and therapy of AD. Methods: Data from the gene expression omnibus (GEO) database were analyzed. Hub genes related to disulfide levels, NAD+ metabolism, and AD were identified from overlapping genes for differentially expressed genes (DEGs), genes in the NAD+ metabolism or disulfide gene sets, and module genes obtained by weighted gene co-expression network analysis (WGCNA). Pathway analysis of these hub genes was performed by Gene Set Enrichment Analysis (GSEA). A diagnostic model for AD was constructed based on the expression level of hub genes in brain samples. CIBERSORT was used to evaluate immune cell infiltration and immune factors correlating with hub gene expression. The DrugBank database was also used to identify drugs that target the hub genes. Results: We identified 3 hub genes related to disulfide levels in AD and 9 related to NAD+ metabolism in AD. Pathway analysis indicated these 12 genes were correlated with AD. Stepwise regression analysis revealed the area under the curve (AUC) for the predictive model based on the expression of these 12 hub genes in brain tissue was 0.935, indicating good diagnostic performance. Additionally, analysis of immune cell infiltration showed the hub genes played an important role in AD immunity. Finally, 33 drugs targeting 10 hub genes were identified using the DrugBank database. Some of these have been clinically approved and may be useful for AD therapy. Conclusion: Hub genes related to disulfide levels and NAD+ metabolism are promising biomarkers for the diagnosis of AD. These genes may contribute to a better understanding of the pathogenesis of AD, as well as to improved drug therapy.
The etiology of Alzheimer’s disease (AD) is currently unclear. AD is a complex
nervous system disease known to be affected by multiple factors, including
neurotransmitters, immune factors, and environmental factors [1]. Accumulation of
type 2 microtubule-associated (tau) protein is thought to be closely related to
the decline in cognitive function in AD patients. Research has also shown that a
large amount of
Nicotinamide adenine dinucleotide (NAD+) is the coenzyme for many dehydrogenases in the body and also connects the tricarboxylic acid cycle with the respiratory chain. Nicotinamide adenine dinucleotide (NADH) is the reduced form of NAD+, and their interconversion allows mitochondria to generate energy. Beyond its role in energy metabolism, NAD+ is a pivotal signaling molecule essential in mediating various redox reactions, DNA maintenance and repair, gene stability, and epigenetic regulation. Decreased NAD+ levels have been observed in many diseases. In all organisms studied so far, from single-cell yeast to mice and humans, NAD+ levels have been found to decrease with age. This is because aging-induced inflammation promotes the accumulation of cyclic ADP ribohydrolase in immune cells, hinders the cellular synthesis of nicotinamide mononucleotide (NMN), and accelerates NAD+ decomposition. NAD+ metabolism is involved in several neurodegenerative diseases [2], such as AD, Amyotrophic Lateral Sclerosis, and Parkinson’s disease (PD) [3]. The NAD+ level in the brain of AD patients is decreased, and neuroinflammation is increased, leading to neuronal damage and cognitive impairment [4]. Restoration of NAD+ levels may ameliorate the various disease phenotypes by activating mitochondrial functions [5].
Under conditions of glucose starvation, high levels of SLC7A11 expression
(SLC7A11
The above findings suggest that disulfides and NAD+ metabolism may act together to regulate disease. We, therefore, speculated that disulfide levels and NAD+ metabolism may be related to AD.
To date, there have been no reports on hub genes in the disulfide levels and NAD+ metabolic pathways in relation to the diagnosis of AD and as possible targets for this disease. The aim of this study was, therefore, to identify hub genes for disulfide levels and NAD+ metabolism in AD.
The differentially expressed genes (DEGs) expression dataset was obtained from the Gene Expression Omnibus (GEO) public database in NCBI (https://www.ncbi.nlm.nih.gov/geo/). GSE132903 was selected for analysis of DEGs from AD patients compared with controls, which is based on platform GPL10558 and contains 97 AD samples and 98 controls [12]. Two datasets from blood, GSE63060 (145 AD and 104 controls) and GSE63061 (139 AD and 134 controls), were used as the external validation cohorts to examine the diagnostic value of hub genes. Details of the data selected are described in Table 1.
GEO accession number | Sample size (AD/control) | Platform |
GSE132903 (Middle temporal gyrus) | AD = 97 | GPL10558 Illumina HumanHT-12 V4.0 expression beadchip |
HC = 98 | ||
GSE63060 (Blood) | AD = 145 | GPL6947 Illumina HumanHT-12 V3.0 expression beadchip |
HC = 104 | ||
GSE63061 (Blood) | AD = 139 | GPL10558 Illumina HumanHT-12 V4.0 expression beadchip |
HC = 134 |
CEO, Gene Expression Omnibus; AD, Alzheimer’s disease; HC, Healthy control; GPL, Gene chip platform.
We used the “limma” package
(https://www.bioconductor.org/packages/release/bioc/html/limma.html) to identify
DEGs between AD and control cases. First, we removed genes with an expression
value of 0 and a ratio
We screened 10 disulfide levels-related gene datasets (Supplementary Table 1) from the Molecular Signatures Database (MSigDB, https://www.gsea-msigdb.org/gsea/msigdb/index.jsp) and Kyoto Encyclopedia of Genes and Genomes (KEGG, https://www.kegg.jp/). After the removal of overlapping genes, 283 disulfide levels-related genes (DLRGs) were identified (Supplementary Table 2).
We also screened 64 NAD+ metabolism-related gene datasets (Supplementary Table 1) from the Molecular Signatures Database (MSigDB). After the removal of overlapping genes, 496 NAD+ metabolism-related genes (NMRGs) were identified (Supplementary Table 2).
Weighted gene co-expression network analysis (WGCNA) identifies gene sets of
interest using information from thousands of genes that show the greatest
changes. It performs significant correlation analysis with the phenotype and
reveals interaction patterns between the genes in each sample [13]. WGCNA was
used here to analyze key modules in order to understand gene association patterns
between different samples. First, the median absolute deviation (MAD) of each
gene was calculated, and those with a MAD
In order to identify hub genes related to both NAD+ metabolism and AD, the DEGs, genes in the NAD+ metabolism gene sets, and module genes identified by WGCNA were screened using a Venn diagram. To identify hub genes related to both disulfide levels and AD, the DEGs, genes in the disulfide levels gene sets, and module genes identified by WGCNA were also screened using a Venn diagram. Differences in the expression of hub NMRGs and DLRGs between AD and control samples were displayed by violin plot.
Pathway analysis was conducted to explore the mechanism by which hub NMRGs and
DLRGs could be associated with AD. Gene set enrichment analysis (GSEA) reveals
the distribution trend of each gene in the gene table sorted by phenotype
correlation, thereby allowing evaluation of the effect of synergistic changes in
genes on phenotypic changes. Samples were divided into low- and high-expression
groups according to the average expression level of hub NMRGs and DLRGs.
Background gene sets were downloaded from the Molecular Signatures Database
(https://www.gsea-msigdb.org/gsea/msigdb/index.jsp) to evaluate the relevant
pathways and molecular mechanisms involving hub NMRGs and DLRGs. The thresholds
for selecting targets were p
Cox’s proportional hazards regression model (Cox regression model) is used mainly for the prognostic analysis of tumors and other chronic diseases but can also be used to explore etiology in cohort studies. It is widely used in clinical practice, with the results obtained often having direct clinical applications. Cox analysis plays a crucial role in the clinical diagnosis of AD. In this study, expression levels for the 12 hub DLRGs and NMRGs were first adjusted for covariates such as sex and age (Supplementary Tables 3–5). The “survival” package in R (version 4.1.2) (R package, University of California, Los Angeles, LA, USA) was then used to integrate survival time, survival status, and expression levels for the 12 hub DLRGs and NMRGs. Cox analysis was used to evaluate the prognostic significance of the 12 hub genes in samples from GSE132903, GSE63060, and GSE63061 and to obtain the RiskScore. Diagnostic receiver operating characteristic curve (ROC) analysis was performed using the roc function of “pROC” packages (version 1.17.0.1) (https://www.rdocumentation.org/packages/pROC/versions/1.17.0.1) in R software. The ci function of the “pROC” package in R software was then used to evaluate the area under the ROC curve (AUC) and the confidence intervals. Next, the diagnostic ROC model was applied to samples from GSE132903, GSE63060, and GSE63061 using only demographic information such as sex and age. Finally, the log-rank test was performed to compare the two models and thus determine the additional value gained from the 12 hub genes.
The infiltration of immunocytes in AD and control samples from GSE132903 was evaluated using CIBERSORT (https://cibersortx.stanford.edu/) based on gene expression data. Spearman correlation analysis was performed between the 12 hub DLRGs and NMRGs and various immune factors, immune infiltration, and major histocompatibility complex (MHC) using the “psych” package in R software (version 4.1.2) (R package, University of California, Los Angeles, LA, USA). Immune factors and MHC were downloaded from the TISIDB database (http://cis.hku.hk/TISIDB/) [14]. These included 24 immuno-inhibitors, 46 immuno-stimulators, 41 chemokines, and 21 MHCs.
We searched the DrugBank database (https://go.drugbank.com) (University of Alberta, Edmonton, Alberta, Canada) [15] for possible targeted drugs against the hub genes. The DrugBank database integrates bioinformatics and chemical informatics to provide detailed drug data, target information, and comprehensive information on their mechanism of action, including drug chemistry, pharmacology, pharmacokinetics and interactions. The latest version of DrugBank (5.1.10) was released on January 4, 2023, and contained 15,664 drug entries, including 2742 approved small molecule drugs, 1584 approved biologic agents (proteins, peptides, vaccines, and allergens), 134 nutritional products, and 6720 experimental drugs.
To investigate the changes in gene expression that occur in AD, we screened for
DEGs between the AD and control groups. DEGs are displayed in a volcano plot in
Fig. 1A, and the top 20 DEGs are shown in a heatmap in Fig. 1B. Using a threshold
of p
Differentially expressed genes between AD and control samples. (A) The upregulated mRNAs are shown in red, and the downregulated mRNAs in green. Grey indicates no significant change. (B) The top 20 DEGs between the AD and control groups are shown as a heatmap. AD, Alzheimer’s disease.
We next performed WGCNA of these DEGs to identify those that play a significant
role in the pathological mechanism of AD. The parameters selected for WGCNA were
a soft threshold of 12, a scale independence of 0.87, and an average connectivity
of 30.42 (Fig. 2A,B). With threshold values of 0.25 for mergeCutHeight and 30
for minModuleSize, 16 co-expression modules were acquired (Fig. 3A,B).
Correlations between each module and AD features were then analyzed (Fig. 3C).
The strongest positive correlation with AD was seen with the grey60 module (r =
0.42, p = 1.0
Results from WGCNA based on gene expression profile. (A) The correlative scale-free topology fit indexes under the selected parameter. The horizontal axis is the soft threshold (power), while the vertical axis is the evaluation parameter of the scale-free network. The higher the value, the more the network conforms to the scale-free characteristics. (B) The correlative mean connectivity values under the selected parameter. The horizontal axis is the soft threshold (power), while the vertical axis represents the mean of all gene adjacency functions in the corresponding gene module. WGCNA, weighted gene co-expression network analysis.
Results of the WGCNA. (A) Gene cluster dendrogram. Different branches of the cluster dendrogram represent different gene modules, with different colors representing different modules. (B) Correlation heatmap between modules obtained based on the clustering of gene expression levels. The heatmap can be divided into two parts, with the upper part clustering the modules according to their eigengenes. The ordinate represents the dissimilarity of nodes, with each module represented by different colors. The abscissa and ordinate in the lower half of the figure represent different modules. Weaker correlations are more blue, while stronger correlations are more red. (C) Correlations between different modules and clinical traits. The abscissa represents different samples, while the ordinate represents different modules. The higher the absolute value of the correlation between a trait and a module, the stronger the correlation between the gene function of the trait and the module. The positive correlation is indicated by the red color, and the negative correlation is indicated by the green color. Correlations between the membership relationship and gene significance in the royal blue module (D), dark grey module (E), and grey60 module (F).
Identification of NMRGs and DLRG. (A) Nine hub NMRGs were identified from the overlap of genes between DEGs, NMRGs, and genes in selected modules obtained by WGCNA. (B) Three hub DLRGs were identified from the overlap of genes between DEGs, DLRGs, and genes in selected modules obtained by WGCNA. (C) Expression of the hub DLRGs and NMRGs in the AD and control groups from GSE132903. NMRGs, NAD+ metabolism-related genes; DEGs, differentially expressed genes; NMRGs, NAD+ metabolism-related genes; DLRGs, disulfide levels-related genes.
Pathway analysis of the hub DLRGs and NMRGs was conducted to study possible biological mechanisms relating to AD. The putative functions of the 12 hub DLRGs and NMRGs in AD were analyzed by GSEA (Fig. 5A–L).
GSEA was used to analyze the putative functions of the 12 hub DLRGs and NMRGs in AD. (A) GOT1, (B) CYP26B1, (C) MICAL2, (D) NDUFAB1, (E) SNCA, (F) ENO2, (G) TPI1, (H) NUBPL, (I) PGAM1, (J) GLRX, (K)TMX3, and (L) LIME1. GSEA, Gene set enrichment analysis; GOT1, glutamic-oxaloacetic transaminase 1; CYP26B1, cytochrome P450 family 26 subfamily B member 1; MICAL2, microtubule associated monooxygenase, calponin and LIM domain containing 2; NDUFAB1, NADH: ubiquinone oxidoreductase subunit AB1; SNCA, synuclein alpha; ENO2, enolase 2; TPI1, triosephosphate isomerase 1; NUBPL, NUBP iron-sulfur cluster assembly factor, mitochondrial; PGAM1, phosphoglycerate mutase 1; GLRX, glutaredoxin; TMX3, thioredoxin related transmembrane protein 3; LIME1, Lck interacting transmembrane adaptor 1.
A predictive model was constructed to test the diagnostic value of the hub genes. Using stepwise regression analysis, the 3 hub DLRGs and 9 hub NMRGs were selected to build an optimal model. The AUC of this predictive model was 0.935 in brain tissue samples, suggesting the 12 hub DLRGs and NMRGs had good diagnostic performance (Fig. 6A). The diagnostic value of the hub genes was next examined in blood samples. Using the model, the AUCs obtained in the GSE63061 and GSE63060 cohorts were 0.740 and 0.705, respectively (Fig. 6B,C). The higher AUC observed in brain samples indicates the diagnostic superiority of this tissue source. However, because of the difficulty in obtaining brain tissue, models that produce good results using blood samples may be helpful for the early diagnosis of AD patients. In order to confirm the added value of these genes,diagnostic ROC analysis of the GSE132903, GSE63060 and GSE63061 cohorts was performed using a model containing only demographic factors such as sex and age(Fig. 6D,E,F).
Diagnostic ROC and relevant AUC values for the three AD cohorts. Diagnostic ROC analysis of the (A) GSE132903, (B) GSE63060, and (C) GSE63061 cohorts using a model containing expression levels for the 12 hub DLRGs and NMRGs, and adjusted for covariates such as sex and age. Diagnostic ROC analysis of the (D) GSE132903, (E) GSE63060, and (F) GSE63061 cohorts using a model containing only demographic factors such as sex and age. ROC, receiver operating characteristic; AUC, area under the curve.
To estimate the additional diagnostic value provided by the 12 hub genes, ROC
models that included only demographic factors such as sex and age were used for
the GSE132903, GSE63060, and GSE63061 cohorts. The AUC value of 0.504 obtained
for the GSE132903 cohort was significantly lower (p
We next analyzed the infiltration of immunocytes in AD by evaluating the
proportion of 22 immune cell types in AD and control samples using the CIBERSORT
algorithm (Fig. 7A). Correlation analysis showed that macrophages M2 and
neutrophils had a synergistic effect. Furthermore, macrophages M0 and macrophages
M2 showed the strongest competitive effect (Fig. 7B). A violin plot was used to
show differences in the immune infiltration score between AD and control groups
(Fig. 7C). The AD group had significantly higher proportions of B cells naive
(p = 0.02) and neutrophils (p = 0.01) than the control group,
whereas the proportions of macrophages M1 (p = 1.5
Comparison of immunocyte infiltration between AD and control samples. (A) The percentage of 22 immune cell types in each sample. (B) Co-expression patterns between the different types of immune cells. Red: positive correlation; Blue: negative correlation. (C) Immune infiltration score in the AD and control samples. * represents the correlation coefficient bigger than 0.1 but less than 0.2. ** represents the correlation coefficient bigger than 0.2 but less than 0.35. *** represents the correlation coefficient bigger than 0.35 but less than 0.4. **** represents the correlation coefficient bigger than 0.4.
Spearman correlation analysis of the 12 hub DLRGs and NMRGs with (A) immune cells, (B) immune inhibitors, (C) chemokines, (D) immune stimulators, and (E) MHC. Green: positive correlation; Red: negative correlation; *, significant difference. MHC, major histocompatibility complex.
Based on drug and target information from the DrugBank database, we identified 33 drugs targeting 10 hub DLRGs and NMRGs (Fig. 9). Of these, 17 have been approved, 2 are investigational, and 12 are experimental. Adapalene (DB00210), an inhibitor of GOT1, is used to treat acne vulgaris. Molecular docking has shown that adapalene coordinates with GOT1 at its allosteric site with low binding energy. Knockout of GOT1 reduces cell sensitivity to the anti-proliferative effect of adapalene. This drug is reported to inhibit the growth of ES-2 ovarian cancer cells by targeting glutamic-oxaloacetic transaminase 1 (GOT1). Copper (DB09130) targets SCNA, GOT1, MICAL2, PGAM1, and TMX3 and is used for total parenteral nutrition supplementation and intrauterine device contraception. The effect of low-dose copper on PGAM1 was tested by 2-dimensional fluorescence difference gel electrophoresis coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS/MS). This showed that copper significantly down-regulates the expression of PGAM1 [16]. Pyridoxal phosphate (DB00114) is an activator of GOT1 and is used for nutritional supplementation. In silico docking analysis suggests that GOT1 inhibitor competes for binding to the pyridoxal phosphate cofactor site of GOT1. Mutational studies have revealed the relationship between pyridoxal phosphate binding and the thermal stability of GOT1 [16]. Zinc chloride (DB14533) binds to TPI1 and TMX3 and is used to maintain zinc serum levels and prevent deficiency syndromes. Zinc sulfate (DB14548) also binds to TPI1 and TMX3 and is used for zinc supplementation in parenteral nutrition. Artenimol (DB11638) targets TMX3, PGAM1, and TPI1 and is used to treat uncomplicated plasmodium falciparum infection. Aspartic acid (DB00128) targets GOT1 and is used to enhance exercise performance. Cysteine (DB00151) targets GOT1 and is used to prevent liver and kidney damage associated with acetaminophen overdose. Glutamic acid (DB00142) targets GOT1 and is used to improve mental capacity. Vitamin A (DB00162) is a substrate inducer of CYP26B1 and is used to treat vitamin A deficiency. Tretinoin (DB00755) is a substrate of CYP26B1 and is used to induce remission from acute promyelocytic leukemia in adult patients and pediatric patients older than 1 year. Human calcitonin (DB06773) targets MICAL2 and is used to treat Paget’s disease. NADH (DB00157) targets NADH: ubiquinone oxidoreductase subunit AB1 (NDUFAB1) and is used to treat many neurodegenerative diseases. Zinc (DB01593) targets TPI1 and TMX3 and is used to treat and prevent zinc deficiency and its consequences. Zinc acetate (DB14487) also targets TPI1 and TMX3 and is used to treat and prevent zinc deficiency and its consequences, to boost the immune system, and to treat the common cold and recurrent ear infections. Glutathione (DB00143) targets GLRX and is used for nutritional supplementation and the treatment of dietary deficiency or imbalance.
Drugs targeting 10 hub DLRGs and NMRGs, as identified in the DrugBank database. The drug status (approved, investigational, nutraceutical, or experimental) is indicated by the colored circles.
Nicotinamide adenine dinucleotide consists of oxidized (NAD+) and reduced (NADH)
forms. NAD+ is a major coenzyme in the tricarboxylic acid cycle and can influence
many key cell functions, including DNA repair, chromatin remodeling, immune cell
function, and cell aging. Aging is closely related to most neurodegenerative
diseases and is associated with decreased cellular levels of NAD+ in the brain
[17]. Depletion of NAD+ has been found in several models of accelerated aging
that exhibit certain characteristics of neurodegenerative disease [5]. Recent
studies have also found that high levels of accumulated disulfides result in
abnormal disulfide binding between actin cytoskeleton proteins, eventually
leading to a collapse of the actin network and cell death [6]. Reduced actin is
significantly correlated with cognitive impairment and with A
In the current study, 3 genes related to AD and disulfide levels were identified
(GLRX, TMX3, and LIME1), as well as 9 genes related to
AD and NAD+ metabolism (GOT1, CYP26B1, MICAL2,
NDUFAB1, SNCA, ENO2, TPI1, NUBPL and
PGAM1). Pathway analysis revealed these genes were involved in AD.
Furthermore, Gene Ontology (GO) enrichment analysis showed they were involved in
oxidation-reduction and NADH regeneration processes to regulate the function of
mitochondria. Abnormal expression of these genes leads to dysfunction of
mitochondria and the production of reactive oxygen species (ROS) in the cell microenvironment [18]. Excess
ROS can damage biological cell macromolecules such as proteins, nucleic acids,
and lipids. This affects their normal physiological functions, eventually leading
to necrosis and apoptosis and accelerating the occurrence and development of AD
[19]. As a metabolic cofactor, NAD+ plays a crucial role in mitochondrial
function. Wu et al. [20] proposed that ROS formation induced by
A
We constructed a diagnostic model to determine whether the 12 hub DLRGs and NMRGs identified in AD patients could predict prognosis in clinical applications. The AUC for this predictive model was 0.935 using brain tissue samples and 0.740 and 0.705 using blood samples, indicating good diagnostic performance with the 12 hub DLRGs and NMRGs. The blood sample model allows clinical diagnosis of AD patients in cases where it is difficult to obtain brain tissue. GOT1 is considered to be a key metabolic gene related to AD [21] and codes for glutamic oxaloacetic transaminase in the cytoplasm. This gene was reported to be downregulated in the elderly population and AD patients [22]. Retinoic acid (RA) is metabolized into an inactive form by CYP26B1, which is a member of the cytochrome P450 enzyme family. Decreased CYP26B1 levels have been reported in a mouse model of AD [23]. NDUFAB1 is a novel molecule that enhances mitochondrial metabolism and is associated with signaling pathways for oxidative phosphorylation [24]. Musculoskeletal aging and AD show an imbalance in the expression of NDUFAB1 [25]. Synuclein alpha (SNCA) is thought to be associated with memory, learning abilities, and neurodegenerative diseases [26]. Single nucleotide polymorphisms in SNCA, such as rs3857059, rs2583988, and rs10516846, have been associated with a higher risk of AD [27, 28]. The enolase ENO2 is expressed mainly in neurons of the whole neuraxis [29] and is regarded as a diagnostic marker for AD [30].
The enzyme triose phosphate isomerase (TPI) catalyzes the reversible conversion between dihydroxyacetone phosphate isomers and glyceraldehyde 3-phosphate. Deletion of TPI has been shown to induce neurologic abnormalities, and TPI could also be a hub gene that participates in the molecular pathogenesis of AD [31, 32]. Phosphoglycerate mutase 1 (PGAM1) is a major enzyme in the glycolysis pathway and is very sensitive to oxidative stress. PGAM1 can inhibit glycolysis and is prone to oxidation in neurological diseases such as AD [33, 34]. Glutaredoxin (GLRX) is a major member of the thiol/disulfide bond oxidoreductase family that catalyzes redox reactions between glutathione (GSH) and protein disulfide bonds. Abnormalities in the aggregation, structure, and function of actin have been found to affect dendritic spines in AD [35]. Overexpression of GLRX1 can rescue these deficits by restoring F-actin dynamics in dendritic spines. Another actin modulator, LIM domain kinase 1 (LIMK1), was also reported to be involved in the assembly and decomposition of F-actin in AD [36]. Thioredoxin related transmembrane protein 3 (TMX3) is a member of the disulfide isomerase family of endoplasmic reticulum proteins. Decreased expression of TMX3 was reported in association with mutant huntingtin protein [37]. However, further research is needed to determine whether upregulation of TMX3 expression in the brain could improve neurodegeneration.
The pathogenesis of AD is not limited to neuronal regions, with many brain
immune cells such as astrocytes, macrophages (microglia in the brain), and
peripheral infiltrating immune cells also being involved. The infiltration of
immunocytes and immune factors was investigated in the present study, with box
plots used to show the marked differences in immunocytes between AD and control
groups. The level of infiltration by naive B cells was higher in the AD group, in
accordance with a previous study [38]. Neutrophils were also more common in the
brain of AD patients, with these cells usually being the first responders to
inflammation [39]. Neuroinflammation is a significant factor in the pathogenesis
and development of AD. An increased level of CD11b integrin was reported in the
peripheral blood neutrophils of AD patients [40]. In addition, neutrophils have
been shown to accumulate in AD and have been implicated in its pathology and
associated cognitive impairment [41]. Moreover, the depletion of neutrophils
resulted in decreased levels of phosphorylated tau in a mouse model of AD. In the
current study, significant correlations were found between 12 hub DLRGs and NMRGs
and different immune factors and are shown using heatmaps. Correlations between
AD and immune, inflammatory, and cell death pathways were also confirmed. Immune
signaling and cell death pathways ultimately cause the release of cytokines and
chemokines that participate in pro-inflammatory and anti-inflammatory processes,
neuron injury, and microglial effects on A
Besides cytokines, chemokines also enhance local inflammation in AD by regulating the migration of microglia to the neuroinflammatory region. C-X3-C motif chemokine ligand 1 (CX3CL1) is the only member of the chemokine CX3C family and is commonly present in the entire brain, particularly in neural cells. The levels of CX3CL1 were reported to be significantly reduced in the hippocampus, frontal cortex, and cerebrospinal fluid of AD patients compared to healthy controls [45]. Unlike other chemokines, CX3CL1 only interacts with the C-X3-C motif chemokine receptor 1 (CX3CR1) expressed on microglia and hence plays a crucial role in neuron-microglial communication [46]. It has been suggested that abnormal CX3CL1/CX3CR1 signaling could affect AD pathogenesis and progression [47]. Chemokine (C-X-C motif) ligand 1 (CXCL1) is a significant member of the CXC chemokine family and binds to the CXCR2 receptor. CXCL1 is found in various cell types, including neutrophils and oligodendrocytes, and may have important pro-nociceptive effects through direct effects on sensory neurons. CXCL1 has been shown to activate caspase-3-dependent tau proteins, resulting in the aberrant extracellular distribution of these abnormal tau proteins [48].
We identified 33 drugs in the DrugBank database that target 10 of the hub genes.
Copper is an essential biomolecule in human physiology and plays an important
role against oxidative stress [49]. Disruptions in the metabolism and
distribution of copper have been reported in AD patients. An indicator of
abnormal copper metabolism is increased levels of non-ceruloplasmin copper, which
has been associated with a higher risk of AD [50]. Copper (DB09130) is considered
to be a potential therapeutic target for AD due to its redox ability.
Consequently, a large number of ligands have been developed to disrupt the
A
In conclusion, we identified 12 hub genes that link disulfide levels and NAD+ metabolism with AD. The pathways enriched by these genes may help to shed light on the mechanism of AD pathogenesis. However, further experiments are needed to confirm the functions of these hub genes. We built a diagnostic model for the diagnosis of AD based on the expression levels for the 12 DLRGs and NMRGs in brain and blood samples. Moreover, these genes were found to be associated with distinct immune factors, indicating they play a major role in the immune microenvironment. Our study also predicted drugs that could be used to target the hub genes, thus providing valuable insights for the treatment of AD.
All the data supporting the results of this study are included in the manuscript and the Supplementary Documents.
LS and YW designed the study. LS, YZ and YW performed the data analysis. YW and LS wrote the manuscript. HW collected and sort references, designed and drew the figures and tables. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.
Not applicable.
Not applicable.
This work was supported by excellent youth fund for basic scientific research projects of Hebei North University (JYT2023002), youth fund for basic scientific research projects of Hebei North University (JYT2022008) and the Project of Hebei North University (H2022405030), China.
The authors declare no conflict of interest.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.